Initial Statement of Beneficial Ownership (3)

FORM 3	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES	OMB APPROVAL OMB Number: 3235-0104 Estimated average burden hours per response... 0.5
	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person ^*

Cline Christopher R.

2. Date of Event Requiring Statement (MM/DD/YYYY) 9/1/2022

3. Issuer Name and Ticker or Trading Symbol

Travere Therapeutics, Inc. [TVTX]

(Last) (First) (Middle)

C/O TRAVERE THERAPEUTICS, INC., 3611 VALLEY CENTRE DRIVE, STE 300

4. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director _____ 10% Owner
___X___ Officer (give title below) _____ Other (specify below)
Chief Financial Officer /

(Street)

SAN DIEGO, CA 92130

(City) (State) (Zip)

5. If Amendment, Date Original Filed(MM/DD/YYYY)

6. Individual or Joint/Group Filing(Check Applicable Line)

_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	28723	D

*Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)*
1. Title of Derivate Security (Instr. 4)	2. Date Exercisable and Expiration Date (MM/DD/YYYY)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivate Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security		6. Nature of Indirect Beneficial Ownership (Instr. 5)
Employee Stock Option (Right to Buy)	⁽¹⁾	8/10/2024	Common Stock	40000	$12.51	D
Employee Stock Option (Right to Buy)	⁽¹⁾	6/30/2025	Common Stock	15000	$32.49	D
Employee Stock Option (Right to Buy)	⁽¹⁾	5/18/2026	Common Stock	20000	$16.23	D
Employee Stock Option (Right to Buy)	⁽¹⁾	5/16/2027	Common Stock	20000	$17.44	D
Employee Stock Option (Right to Buy)	⁽¹⁾	5/9/2028	Common Stock	12500	$25.25	D
Employee Stock Option (Right to Buy)	⁽²⁾	5/8/2029	Common Stock	10000	$17.96	D
Employee Stock Option (Right to Buy)	⁽³⁾	1/30/2030	Common Stock	12500	$15.46	D
Employee Stock Option (Right to Buy)	⁽⁴⁾	1/20/2031	Common Stock	16250	$26.88	D
Employee Stock Option (Right to Buy)	⁽⁵⁾	1/30/2032	Common Stock	17500	$27.50	D
Employee Stock Option (Right to Buy)	⁽⁶⁾	4/9/2032	Common Stock	5000	$28.55	D

Explanation of Responses:
(1)	The stock option is fully vested and exercisable.
(2)	One-fourth of the shares subject to the stock option vested and become exercisable on May 9, 2020, and the remaining shares vest in 36 equal monthly installments thereafter.
(3)	One-fourth of the shares subject to the stock option vested and become exercisable on January 31, 2021, and the remaining shares vest in 36 equal monthly installments thereafter.
(4)	One-fourth of the shares subject to the stock option vested and became exercisable on January 21, 2022, and the remaining shares vest in 36 equal monthly installments thereafter.
(5)	One-fourth of the shares subject to the stock option will vest and become exercisable on January 31, 2023, and the remaining shares vest in 36 equal monthly installments thereafter.
(6)	One-fourth of the shares subject to the stock option will vest and become exercisable on April 10, 2023, and the remaining shares vest in 36 equal monthly installments thereafter.

Reporting Owners
Reporting Owner Name / Address	Relationships
Reporting Owner Name / Address	Director	10% Owner	Officer	Other
Cline Christopher R. C/O TRAVERE THERAPEUTICS, INC. 3611 VALLEY CENTRE DRIVE, STE 300 SAN DIEGO, CA 92130			Chief Financial Officer

Signatures
/s/ Elizabeth E. Reed, Attorney-in-Fact		9/1/2022
^**Signature of Reporting Person		Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
*	If the form is filed by more than one reporting person, see Instruction 5(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note:	File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.